Download PDF
Thromb Haemost 2005; 93(06): 1021-1026
DOI: 10.1160/TH04-11-0768
Review Article
Schattauer GmbH

Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?

A meta-analysis of thrombophilic factors
Mirian C. H. Janssen
1   Department of General Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands
,
Martin den Heijer
2   Department of Endocrinology and Epidemiology and Biostatistics, Radboud University Medical Centre, Nijmegen, The Netherlands
,
Johannes R. M. Cruysberg
3   Department of Ophtalmology Radboud University Medical Centre, Nijmegen, The Netherlands
,
Hub Wollersheim
1   Department of General Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands
4   Centre for Quality of Care Research, Radboud University Medical Centre, Nijmegen, The Netherlands
,
Sebastian J. H. Bredie
1   Department of General Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 29 November 2004

Accepted after revision 08 March 2005

Publication Date:
11 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Previous studies have shown an increased risk of retinal vein occlusion (RVO) in patients with hypertension, hypercholesterolemia and diabetes mellitus. Literature on the association between thrombophilic factors and RVO consists of small studies and case reports. The objective was to determine the relationship between thrombophilic risk factors and RVO. Thrombophilic risk factors analyzed were hyperhomocysteinemia, MTHFR gene mutation, factor V Leiden mutation, protein C and S deficiency, antithrombin deficiency, prothrombin gene mutation, anticardiolipin antibodies and lupus anticoagulant. For all currently known thrombophilic risk factors odds ratios for RVO were calculated as estimates of relative risk. The odds ratios were 8.9 (95% CI 5.7 –13.7) for hyperhomocysteinemia, 3.9 (95% CI 2.3 – 6.7) for anticardiolipin antibodies, 1.2 (95% CI 0.9 –1.6) for MTHFR, 1.5 (95% CI 1.0 – 2.2) for factor V Leiden mutation and 1.6 (95% CI 0.8 – 3.2) for prothrombin gene mutation. In conclusion, regarding thrombophilic risk factors and RVO there is only evidence for an association with hyperhomocysteinemia and anticardiolipin antibodies, factors that are known as risk factors for venous thrombosis as well as for arterial vascular disease. The minor effect of factor V Leiden mutation and the protrombin gene mutation (risk factors for venous thrombosis only) suggests that atherosclerosis might be an important factor in the development of CRVO.

Keywords

Retinal vein thrombosis - retinal vein occlusion - risk factors - hyperhomocysteinemia - anticardiolipin antibodies
 

  • References

  • 1 David R, Zangwill L, Badarna M. et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197: 69-74.
    CrossrefPubMedGoogle Scholar
  • 2 Beaumont PE, Kang HK. Clinical characteristics of retinal venous occlusions occurring at different sites. Br J Ophthalmol 2002; 86: 572-80.
    CrossrefPubMedGoogle Scholar
  • 3 Williamson TH. Central retinal vein occlusion: what's the story?. Br J Ophthalmol 1997; 81: 698-704.
    CrossrefPubMedGoogle Scholar
  • 4 Dryden RM. Central retinal vein occlusions and chronic simple glaucoma. Arch Ophthalmol 1965; 73: 659-63.
    CrossrefPubMedGoogle Scholar
  • 5 Vannas S, Tarkkanen A. Retinal vein occlusion and glaucoma: tonographic study of the incidence of glaucoma and of its prognosic significance. Br J Ophtalmol 1960; 44: 583-89.
    CrossrefPubMedGoogle Scholar
  • 6 Hayreh SS, Zimmerman B, McCarthy MJ. et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
    CrossrefPubMedGoogle Scholar
  • 7 Johnston RL, Brucker AJ, Steinmann W. et al. Risk factors of branch retinal vein occlusion. Arch Ophthalmol 1985; 103: 1831-32.
    CrossrefPubMedGoogle Scholar
  • 8 Prisco D, Marcucci R, Bertini L. et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med 2002; 13: 163-9.
    CrossrefPubMedGoogle Scholar
  • 9 Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-11.
    CrossrefPubMedGoogle Scholar
  • 10 Rath EZ, Frank RN, Shin DH. et al. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992; 99: 509-14.
    CrossrefPubMedGoogle Scholar
  • 11 Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000; 11: 462-67.
    CrossrefPubMedGoogle Scholar
  • 12 Robinson MK, Halpern JI. Retinal vein occlusion. Am Fam Physician 1992; 45: 2661-6.
    PubMedGoogle Scholar
  • 13 Sperduto RD, Hiller R, Chew E. et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998; 105: 765-71.
    CrossrefPubMedGoogle Scholar
  • 14 Swart J, Reichert-Thoen JW, Suttorp Schulten MS. et al. Diabetes mellitus: a risk factor affecting visual outcome in branch retinal vein occlusion. Eur J Ophthalmol 2003; 13: 648-52.
    CrossrefPubMedGoogle Scholar
  • 15 Wenzler EM, Rademakers AJ, Boers GH. et al. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-7.
    CrossrefPubMedGoogle Scholar
  • 16 Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stata. Systematic reviews 2001; 347: 69.
    PubMedGoogle Scholar
  • 17 Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-3.
    CrossrefPubMedGoogle Scholar
  • 18 Abu El-Asrar AM, Abdel Gader AG, Al Amro SA. et al. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002; 12: 495-500.
    CrossrefPubMedGoogle Scholar
  • 19 Adamczuk YP, Iglesias Varela ML, Martinuzzo ME. et al. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002; 13: 623-6.
    CrossrefPubMedGoogle Scholar
  • 20 Brown BA, Marx JL, Ward TP. et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109: 287-90.
    CrossrefPubMedGoogle Scholar
  • 21 Cahill M, Karabatzaki M, Meleady R. et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 84: 154-7.
    CrossrefPubMedGoogle Scholar
  • 22 Lahey JM, Tunc M, Kearney J. et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002; 109: 126-31.
    CrossrefPubMedGoogle Scholar
  • 23 Marcucci R, Bertini L, Giusti B. et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-6.
    PubMedGoogle Scholar
  • 24 Pianka P, Almog Y, Man O. et al. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107: 1588-92.
    CrossrefPubMedGoogle Scholar
  • 25 Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 640-4.
    CrossrefPubMedGoogle Scholar
  • 26 Weger M, Stanger O, Deutschmann H. et al. Hyperhomocysteinemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology 2002; 109: 1105-9.
    CrossrefPubMedGoogle Scholar
  • 27 Yildirim C, Yaylali V, Tatlipinar S. et al. Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica 2004; 218: 102-6.
    CrossrefPubMedGoogle Scholar
  • 28 Marcucci R, Giusti B, Betti I. et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003; 110: 7-12.
    CrossrefPubMedGoogle Scholar
  • 29 Boyd S, Owens D, Gin T. et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol 2001; 85: 1313-15.
    CrossrefPubMedGoogle Scholar
  • 30 Cahill M, Karabatzaki M, Donoghue C. et al. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 2001; 85: 88-90.
    CrossrefPubMedGoogle Scholar
  • 31 Cruciani F, Moramarco A, Curto T. et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ther 2003; 154: 299-303.
    PubMedGoogle Scholar
  • 32 Glueck CJ, Bell H, Vadlamani L. et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-9.
    CrossrefPubMedGoogle Scholar
  • 33 Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000; 78: 340-3.
    CrossrefPubMedGoogle Scholar
  • 34 Salomon O, Moisseiev J, Rosenberg N. et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 1998; 9: 617-22.
    CrossrefPubMedGoogle Scholar
  • 35 Weger M, Stanger O, Deutschmann H. et al. Hyperhomocysteinemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 286-90.
    CrossrefPubMedGoogle Scholar
  • 36 Aras S, Yilmaz G, Alpas I. et al. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. Eur J Ophthalmol 2001; 11: 351-5.
    CrossrefPubMedGoogle Scholar
  • 37 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-32.
    CrossrefPubMedGoogle Scholar
  • 38 Demirci FY, Kucukkaya R, Akarcay K. et al. Ocular involvement in primary antiphospholipid syndrome. Int Ophthalmol 1998; 22: 323-9.
    CrossrefPubMedGoogle Scholar
  • 39 Johnson TM, El Defrawy S, Hodge WG. et al. Prevalence of factor V Leiden and activated protein C resistance in central retinal vein occlusion. Retina 2001; 21: 161-6.
    CrossrefPubMedGoogle Scholar
  • 40 Kalayci D, Gurgey A, Guven D. et al. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 622-24.
    CrossrefPubMedGoogle Scholar
  • 41 Marcucci R, Bertini L, Liotta AA. et al. Activated protein C resistance is a risk factor for central retinal vein occlusion. Ann Ital Med Int 2000; 15: 195-8.
    PubMedGoogle Scholar
  • 42 Kadayifcilar S, Ozatli D, Ozcebe O. et al. Is activated factor VII associated with retinal vein occlusion?. Br J Ophthalmol 2001; 85: 1174-8.
    CrossrefPubMedGoogle Scholar
  • 43 Larsson J, Hillarp A, Olafsdottir E. et al. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 634-7.
    CrossrefPubMedGoogle Scholar
  • 44 Tekeli O, Gursel E, Buyurgan H. Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 628-30.
    CrossrefPubMedGoogle Scholar
  • 45 Abu El-Asrar AM, Abdel Gader AG, Al Amro S. et al. Hypercoagulable states in patients with retinal venous occlusion. Doc Ophthalmol 1998; 95: 133-43.
    CrossrefPubMedGoogle Scholar
  • 46 Carbone J, Sanchez-Ramon S, Cobo-Soriano R. et al. Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with ocular inflammatory diseases. J Rheumatol 2001; 28: 2437-41.
    PubMedGoogle Scholar
  • 47 Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ. et al. Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 1999; 128: 725-32.
    CrossrefPubMedGoogle Scholar
  • 48 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a metaanalysis of published epidemiological studies. J Thromb Haemost 2005; 3: 292-9.
    CrossrefPubMedGoogle Scholar
  • 49 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202
    CrossrefPubMedGoogle Scholar
  • 50 den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med 2003; 41: 1404-7.
    PubMedGoogle Scholar
  • 51 den Heijer M, Rosendaal FR, Blom HJ. et al. Hyperhomocysteinemia and venous thrombosis: a metaanalysis. Thromb Haemost 1998; 80: 874-77.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 52 Greiner K, Hafner G, Dick B. et al. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999; 128: 69-74.
    CrossrefPubMedGoogle Scholar
  • 53 Hodgkins PR, Perry DJ, Sawcer SJ. et al. Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 1995; 9: 760-2.
    CrossrefPubMedGoogle Scholar
  • 54 Linna T, Ylikorkala A, Kontula K. et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Harats D, George J, Levy Y. et al. Atheroma: links with antiphopholipid antibodies, Hughes syndrome and lupus. Q J Med 1999; 92: 57-9.
    CrossrefPubMedGoogle Scholar
  • 56 Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-7.
    CrossrefPubMedGoogle Scholar